CIPLA
Back to Income Statement
|
CIPLA Last 5 Year Revenue History
[Consolidated]
| Mar2026 | Mar2025 | Mar2024 | Mar2023 | Mar2022 | |
|---|---|---|---|---|---|
| Net Sales | ₹27,548 Cr | ₹25,774 Cr | ₹22,753 Cr | ₹21,763 Cr | ₹19,160 Cr |
What is the latest Revenue of CIPLA ?
| Year | Revenue |
|---|---|
| Mar2026 | ₹27,548 Cr |
| Mar2025 | ₹25,774 Cr |
| Mar2024 | ₹22,753 Cr |
| Mar2023 | ₹21,763 Cr |
| Mar2022 | ₹19,160 Cr |
How is Revenue of CIPLA Trending?
| Years | Revenue | % Change | |
|---|---|---|---|
| Mar2026 | ₹27,548 Cr | 6.88 | |
| Mar2025 | ₹25,774 Cr | 13.28 | |
| Mar2024 | ₹22,753 Cr | 4.55 | |
| Mar2023 | ₹21,763 Cr | 13.59 | |
| Mar2022 | ₹19,160 Cr | - | |
Compare Revenue of peers of CIPLA
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| CIPLA | ₹111,894.2 Cr | -2.2% | -6.1% | -12.5% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹455,634.0 Cr | -2.9% | -2.3% | 21.8% | Stock Analytics | |
| DIVIS LABORATORIES | ₹241,576.0 Cr | -1.6% | 9.8% | 51.8% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹184,478.0 Cr | -2.6% | -2.3% | 37.5% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹96,322.1 Cr | -0.9% | -1.8% | -9.8% | Stock Analytics | |
| MANKIND PHARMA | ₹96,179.6 Cr | -2.9% | -4.2% | -6.9% | Stock Analytics | |
CIPLA Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| CIPLA | -2.2% |
-6.1% |
-12.5% |
| SENSEX | -1% |
-2.6% |
-4.1% |
You may also like the below Video Courses